Prevest Denpro Limited (PREVEST) Fair Value & Analysis
Healthcare · IN · Market cap ₹4.7B
Fair value as of: Jul 5, 2026
From 26 valuation models · updated today
Share price +1.8% over the past month.
Price vs Fair Value (12 months)
12‑month range ₹341.80 – ₹604.15 · fair‑value band ₹235.78 – ₹511.32 · the ₹391.75 price screens above the ₹328.28 fair value. As of Jul 5, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
Prevest Denpro Limited (PREVEST) currently trades at ₹391.75, while our model-based Fair Value estimate is ₹328.28 — implying the stock looks roughly 16.2% overvalued today. We read business quality at 58/100 (solid quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: high).
Over the trailing twelve months, Prevest Denpro Limited generated revenue of ₹718M at a net margin of 28.5%. Revenue grew 2.6% year over year. It earns a return on equity of 17.8%. The stock trades on a trailing P/E of 22.9. Fundamentals as of Jul 5, 2026
Our scenario range runs from ₹235.78 (bear case) to ₹511.32 (bull case); at ₹391.75, the current price sits within that range. The share trades about 37% below its 52-week high and 23% above its 52-week low, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -43% fair-value upside — at -16%, PREVEST screens cheaper than that median.
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jul 5, 2026. TTM = trailing twelve months.
About the company
Prevest Denpro Limited engages in the manufacture and distribution of dental materials and equipment in India and internationally. Its clinical products include adhesives, bonding agents, and etchants; composites; impression materials; retraction materials; auxiliaries; endodontics; temporary; cements and liners; finishing and polishing; orthodontics; and tooth whitening products. The company also provides laboratory products, such as acrylics, auxiliaries, base plates and waxes, and gypsum products. In addition, it offers oral care; 3D resins; and hygiene and disinfection products. Its products are used for endodontics, prosthodontics, periodontics, orthodontics, restorative dentistry, and aesthetic dentistry applications, as well as for the fabrication of prosthesis in dental laboratories. Prevest Denpro Limited was incorporated in 1999 and is based in Bari Brahmana, India.
Revenue & earnings trend
FY2022 – FY2026 · reported fiscal years
Prevest Denpro Limited reported revenue of ₹718M in FY2026 versus ₹381M in FY2022, a compound +17.2%/yr. Reported net income was ₹205M in FY2026, compounding +15.4%/yr from FY2022.
Is PREVEST fairly valued? → Check now
Similar stocks
10 more Medical Instruments & Supplies stocks, each showing price versus our Fair Value estimate (as of Jul 5, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Intuitive Surgical, Inc ISRG | $412.02 | $165.35 | -60% |
| EssilorLuxottica Société anonyme ESLOF | $190.25 | $125.65 | -34% |
| HOYA Corporation HOCPY | $168.16 | $96.16 | -43% |
| Medline Inc MDLN | $34.71 | $30.15 | -13% |
| Becton, Dickinson and Company BDX | $149.56 | $117.04 | -22% |
| Alcon Inc ALC | $66.58 | $36.99 | -44% |
| ResMed Inc R1MD34 | R$260.00 | R$32.27 | -88% |
| West Pharmaceutical Services, Inc WST | $330.92 | $114.00 | -66% |
| Terumo Corporation TRUMF | $14.62 | $12.65 | -13% |
| Straumann Holding SAUHY | $13.07 | $5.51 | -58% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Prevest Denpro Limited (PREVEST) undervalued?
What is the fair value of PREVEST?
What is the quality score of PREVEST?
What is the revenue of Prevest Denpro Limited (PREVEST)?
What is the net profit margin of PREVEST?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.